iRhythm Technologies Stock Forecast, Price & News

iRhythm Technologies (NASDAQ:IRTC) Frequently Asked Questions

Is iRhythm Technologies a buy right now?

10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for iRhythm Technologies in the last twelve months. There are currently 7 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" iRhythm Technologies stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in IRTC, but not buy additional shares or sell existing shares.
View analyst ratings for iRhythm Technologies or view top-rated stocks.

How has iRhythm Technologies' stock price been impacted by COVID-19 (Coronavirus)?

iRhythm Technologies' stock was trading at $85.54 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, IRTC shares have increased by 23.5% and is now trading at $105.60.
View which stocks have been most impacted by COVID-19.

When is iRhythm Technologies' next earnings date?

iRhythm Technologies is scheduled to release its next quarterly earnings announcement on Thursday, February 24th 2022.
View our earnings forecast for iRhythm Technologies.

How were iRhythm Technologies' earnings last quarter?

iRhythm Technologies, Inc. (NASDAQ:IRTC) released its quarterly earnings data on Thursday, November, 4th. The company reported ($0.81) EPS for the quarter, beating the consensus estimate of ($1.09) by $0.28. The company had revenue of $85.43 million for the quarter, compared to the consensus estimate of $83.65 million. iRhythm Technologies had a negative trailing twelve-month return on equity of 25.06% and a negative net margin of 24.55%. The company's quarterly revenue was up 18.7% on a year-over-year basis. During the same period in the previous year, the company earned ($0.17) EPS.
View iRhythm Technologies' earnings history.

What guidance has iRhythm Technologies issued on next quarter's earnings?

iRhythm Technologies issued an update on its FY 2021 earnings guidance on Thursday, November, 25th. The company provided EPS guidance of for the period. The company issued revenue guidance of $317 million-$319 million, compared to the consensus revenue estimate of $323.46 million.

What price target have analysts set for IRTC?

10 Wall Street analysts have issued 12-month price objectives for iRhythm Technologies' shares. Their forecasts range from $70.00 to $238.00. On average, they expect iRhythm Technologies' stock price to reach $144.22 in the next year. This suggests a possible upside of 36.6% from the stock's current price.
View analysts' price targets for iRhythm Technologies or view top-rated stocks among Wall Street analysts.

Who are iRhythm Technologies' key executives?

iRhythm Technologies' management team includes the following people:

• Quentin S. Blackford, President, Chief Executive Officer & Director
• Douglas J. Devine, Chief Financial Officer
• Mark J. Day, Executive Vice President-Research & Development
• Judith Lenane, Chief Clinical Officer & Executive VP-Products
• Allan B. Wilsker, EVP-Information Technology & Customer Services

What is Kevin M. King's approval rating as iRhythm Technologies' CEO?

20 employees have rated iRhythm Technologies CEO Kevin M. King on Glassdoor.com. Kevin M. King has an approval rating of 91% among iRhythm Technologies' employees. This puts Kevin M. King in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of iRhythm Technologies' key competitors?

Some companies that are related to iRhythm Technologies include Hill-Rom (HRC), NovoCure (NVCR), Penumbra (PEN), Tandem Diabetes Care (TNDM), ShockWave Medical (SWAV), Globus Medical (GMED), Inspire Medical Systems (INSP), Integra LifeSciences (IART), ICU Medical (ICUI), Inari Medical (NARI), Beauty Health (SKIN), Merit Medical Systems (MMSI), Nevro (NVRO), AtriCure (ATRC) and Haemonetics (HAE).
View all of IRTC's competitors.

What other stocks do shareholders of iRhythm Technologies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other iRhythm Technologies investors own include NVIDIA (NVDA), Alibaba Group (BABA), salesforce.com (CRM), Square (SQ), Teladoc Health (TDOC), Trade Desk (TTD), Advanced Micro Devices (AMD), Intel (INTC), Broadcom (AVGO) and Boeing (BA).

When did iRhythm Technologies IPO?

(IRTC) raised $76 million in an initial public offering (IPO) on Thursday, October 20th 2016. The company issued 5,400,000 shares at $13.00-$15.00 per share. J.P. Morgan and Morgan Stanley acted as the underwriters for the IPO and Canaccord Genuity and BTIG were co-managers.

What is iRhythm Technologies' stock symbol?

iRhythm Technologies trades on the NASDAQ under the ticker symbol "IRTC."

Who are iRhythm Technologies' major shareholders?

iRhythm Technologies' stock is owned by a number of retail and institutional investors. Top institutional investors include Sands Capital Management LLC (11.20%), BlackRock Inc. (7.01%), Mackenzie Financial Corp (6.47%), Credit Suisse AG (3.97%), Wellington Management Group LLP (3.79%) and Vident Investment Advisory LLC (1.96%). Company insiders that own iRhythm Technologies stock include David A Vort, Kevin M King, Mark J Day, Matthew C Garrett, Ralph Snyderman and Raymond W Scott.
View institutional ownership trends for iRhythm Technologies.

Which institutional investors are selling iRhythm Technologies stock?

IRTC stock was sold by a variety of institutional investors in the last quarter, including Capital Research Global Investors, Millennium Management LLC, Assenagon Asset Management S.A., Cubist Systematic Strategies LLC, Renaissance Technologies LLC, Alliancebernstein L.P., Voloridge Investment Management LLC, and Man Group plc.
View insider buying and selling activity for iRhythm Technologies or view top insider-selling stocks.

Which institutional investors are buying iRhythm Technologies stock?

IRTC stock was bought by a variety of institutional investors in the last quarter, including Camber Capital Management LP, Vident Investment Advisory LLC, Bank of New York Mellon Corp, Balyasny Asset Management LLC, Eversept Partners LP, Clough Capital Partners L P, Mackenzie Financial Corp, and Polar Asset Management Partners Inc..
View insider buying and selling activity for iRhythm Technologies or or view top insider-buying stocks.

How do I buy shares of iRhythm Technologies?

Shares of IRTC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is iRhythm Technologies' stock price today?

One share of IRTC stock can currently be purchased for approximately $105.60.

How much money does iRhythm Technologies make?

iRhythm Technologies has a market capitalization of $3.11 billion and generates $265.17 million in revenue each year. The company earns $-43.83 million in net income (profit) each year or ($2.68) on an earnings per share basis.

How many employees does iRhythm Technologies have?

iRhythm Technologies employs 1,157 workers across the globe.

What is iRhythm Technologies' official website?

The official website for iRhythm Technologies is www.irhythmtech.com.

Where are iRhythm Technologies' headquarters?

iRhythm Technologies is headquartered at 650 TOWNSEND STREET SUITE 500, San Francisco CA, 94103.

How can I contact iRhythm Technologies?

iRhythm Technologies' mailing address is 650 TOWNSEND STREET SUITE 500, San Francisco CA, 94103. The company can be reached via phone at (415) 632-5700 or via email at [email protected].